The June 2024 Gastroenterology Month in Review highlights key developments in the field, including the FDA approval of risankizumab-rzaa (Skyrizi) for ulcerative colitis, phase 3 data for mirikizumab in Crohn’s disease, and positive results for guselkumab in Crohn’s disease. Additionally, the latest edition of Qazi Corner covers topics such as bariatric surgery in liver disease and cuffitis outcomes. These updates underscore ongoing advancements and research in gastroenterology.
Previous ArticleInsurers Pocketed $50 Billion From Medicare for Diseases No Doctor Treated (The Wall Street Journal)
Next Article Is Private Equity A Villain In Healthcare? (Forbes)
Keep Reading
Add A Comment